prodigiosin | 6236-12-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: prodigiosin
• 英文别名: Prodigiosine；(2Z)-3-methoxy-2-[(5-methyl-4-pentyl-1H-pyrrol-2-yl)methylidene]-5-(1H-pyrrol-2-yl)pyrrole
• CAS: 6236-12-0
• 化学式: C₂₀H₂₅N₃O
• 分子量: 323.438
• InChiKey: SHUNBVWMKSXXOM-UNOMPAQXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  53.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-甲氧基-2,2'-联吡咯-5-甲醛 、 2-甲基-3-戊基吡咯 以50%的产率得到
  参考文献：
  名称：

  WASSERMAR, HARRY H.;LOMBARDO, LOUIS J., TETRAHEDRON LETT., 30,(1989) N3, C. 1725-1728

  摘要：

  DOI：

文献信息

• Prodigiosin analogs
  申请人：Institute For Cancer Research

  公开号：US10654801B2

  公开（公告）日：2020-05-19

  Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.

  本研究提供了可重新激活 p53 通路的原薯蓣皂苷类似物以及这些化合物的组合物，并提供了使用这些化合物重新激活 p53 通路的方法。原薯蓣皂苷类似物可用于治疗 p53 突变起作用的癌症，包括前列腺癌、乳腺癌、肾癌、卵巢癌、淋巴瘤、白血病和胶质母细胞瘤等。
• Prodigiosin analogs and methods of use
  申请人：Institute for Cancer Research

  公开号：US10870640B2

  公开（公告）日：2020-12-22

  Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.

  本研究提供了可重新激活 p53 通路的原薯蓣皂苷类似物以及这些化合物的组合物，并提供了使用这些化合物重新激活 p53 通路的方法。原薯蓣皂苷类似物可用于治疗 p53 突变起作用的癌症，包括前列腺癌、乳腺癌、肾癌、卵巢癌、淋巴瘤、白血病和胶质母细胞瘤等。
• Prodigiosin Analogs
  申请人：Institute For Cancer Research d/b/a The Research Institute Of Fox Chase Cancer Center

  公开号：US20190119207A1

  公开（公告）日：2019-04-25

  Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
• Prodigiosin Analogs And Methods Of Use
  申请人：Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center

  公开号：US20210139465A1

  公开（公告）日：2021-05-13

  Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
• [EN] PRODIGIOSIN ANALOGS<br/>[FR] ANALOGUES DE LA PRODIGIOSINE
  申请人：INST FOR CANCER RES D/B/A THE RES INST OF FOX CHASE CANCER CENTER

  公开号：WO2017177216A1

  公开（公告）日：2017-10-12

  Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.